Episode

Episode 507: ASCO 2026 - TALAPRO-3

Podcast: The Uromigos
Published: May 30, 2026
Duration seconds: 2505
Processing state: not_requested
Canonical source: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-507-ASCO-2026---TALAPRO-3-e3jqvme
Audio: https://anchor.fm/s/13347ea8/podcast/play/120470670/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-24%2F424794338-44100-2-6d6e4c9015d05.m4a
JSON: /v1/public/podcasts/the-uromigos-1214845/episodes/episode-507-asco-2026-talapro-3
Markdown: /podcast/the-uromigos-1214845/episode-507-asco-2026-talapro-3.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-507-asco-2026-talapro-3/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-uromigos-1214845/episode-507-asco-2026-talapro-3.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.